Spotlight on Internal Medicine

Credits: 1.00 CME / CNE
Cardiac Issues in HIV: Patient Cases
Priscilla Hsue, MD, FACC
American Heart Association

Cardiac Issues in HIV: Patient Cases

Start

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: November 8, 2017
Expires: November 8, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) Assess the clinical aspects of HIV-associated cardiovascular issues
2) Review the HIV-specific issues that are essential for management of CVD in the HIV-infected individual
3) Evaluate the management of CVD in the setting of HIV

Activity Description

This program will assess the clinical aspects of HIV-associated cardiovascular issues, review HIV-specific issues that are essential for the management of CVD in the HIV-infected individual as well as evaluate the management of CVD in the setting of HIV.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - Cardiac Issues in HIV: Patient Cases

15 minutes – Q & A

Presenters

Priscilla Hsue, MD, FACC
William Watt Kerr Professor of Medicine
UCSF School of Medicine
San Francisco, CA


Wendy S. Post, MD, MS
Professor of Medicine and Epidemiology
Division of Cardiology, Department of Medicine
John Hopkins University School of Medicine and
Bloomberg School of Public Health


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 11/08/2017

TERMINATION DATE: 11/08/2020

LAST REVIEW DATE: September 2017

JOINT ACCREDITATION TERM: 11/08/2017 – 11/08/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, Cardiac Issues in HIV: Patient Cases, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 11/08/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Accredited By

American Heart Association

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: November 8, 2017
Expires: November 8, 2020
60 minutes to complete

Target Audience

Physicians (Cardiology, Family Practice, Infectious Disease, HIV Specialist and Internal Medicine); Physician Assistants (Cardiology, Family Practice, Infectious Disease, HIV Specialist, and Internal Medicine); Nurses/Nurse Practitioners; Other (Clinicians involved in the treatment and management of patients with HIV/AIDS)

Learning Objectives

1) Assess the clinical aspects of HIV-associated cardiovascular issues
2) Review the HIV-specific issues that are essential for management of CVD in the HIV-infected individual
3) Evaluate the management of CVD in the setting of HIV

Activity Description

This program will assess the clinical aspects of HIV-associated cardiovascular issues, review HIV-specific issues that are essential for the management of CVD in the HIV-infected individual as well as evaluate the management of CVD in the setting of HIV.

Statement of Educational Need

The program addresses the need for cardiovascular practitioners, family medicine physicians, infectious disease specialists, and other members of the target audience to illustrate the intersection between cardiovascular disease (CVD) and human immunodeficiency virus (HIV) infection.

Agenda

45 minutes - Cardiac Issues in HIV: Patient Cases

15 minutes – Q & A

Presenters

Priscilla Hsue, MD, FACC
William Watt Kerr Professor of Medicine
UCSF School of Medicine
San Francisco, CA


Wendy S. Post, MD, MS
Professor of Medicine and Epidemiology
Division of Cardiology, Department of Medicine
John Hopkins University School of Medicine and
Bloomberg School of Public Health


Planning Committee (Content Developers)

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA
Matthew J. Feinstein, MD
Matthew S. Freiberg, MD, MSc
Mark J. Haykowsky, PhD
Priscilla Hsue, MD
Wendy S. Post, MD, MS
David G. Weismiller, MD ScM, FAAFP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Gerald S. Bloomfield, MD, MPH, FACC, FASE, FAHA – No Disclosures
Matthew J. Feinstein, MD – No Disclosures
Matthew S. Freiberg, MD, MSc – No Disclosures
Mark J. Haykowsky, PhD – No Disclosures
Priscilla Hsue, MD – Honoraria – Gilead; Research Grant – Pfizer; Other Research Support – Novartis
Wendy S. Post, MD, MS – No Disclosures
David G. Weismiller, MD ScM, FAAFP – No Disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 11/08/2017

TERMINATION DATE: 11/08/2020

LAST REVIEW DATE: September 2017

JOINT ACCREDITATION TERM: 11/08/2017 – 11/08/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

AAFP Credit Statement - Physicians
This Enduring Material activity, Cardiac Issues in HIV: Patient Cases, has been reviewed and is acceptable for up to 1.0 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 11/08/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation and Successful Completion

Successful completion of this CE activity includes the following: 

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 80%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Gilead Sciences.

Disclaimer Statement/ Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Luci Ochoa, MBA
Manager, Lifelong Learning, AHA National Center
luci.ochoa@heart.org

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Internal Medicine Presentations

1.00 CME
Integrity Continuing Education, Inc.
Overcoming Barriers to Initiating or Intensifying Insulin Therapy: Best Practices for the Family Physician

Overcoming Barriers to Initiating or Intensifying Insulin Therapy: Best Practices for the Family Physician

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: April 11, 2019
Expires: April 11, 2020
1.0 hour to complete

Provided By

Target Audience

This educational initiative has been designed for family practice and primary care providers (PCPs) involved in the management of patients with diabetes.

Activity Description

A BioDigital Human on-demand simulation activity has been developed as a derivative of the live program content. Simulation decisions and feedback will be supported by evidence-based content and expert faculty explanation.

Learning Objectives

Upon completion of this educational activity, participants will be able to:

  • Articulate clinical strategies for the timely initiation and modification, and intensification of insulin therapy to achieve glycemic control
  • Explain novel strategies to optimize insulin therapy in clinical practice to improve glucose control, reduce risk of weight gain and hypoglycemia, and increase patient access, acceptance and adherence
  • Utilize a patient-centered approach to individualize therapy and appropriately and effectively transition patients to insulin and insulin combinations

Statement of Educational Need

Although practitioners know poor glycemic control puts their patients at increased risk for developing diabetes complications, many delay insulin therapy. This program has been developed to aid family practice clinicians, who are at the frontline of care for these individuals. It will examine the safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) data of newer basal insulin analogs as compared to older insulins. In addition, our faculty will review clinical data on combinations of basal insulin with rapid-acting insulin and GLP-1 receptor agonists and provide updates on newer follow-on insulin therapies. The ultimate goal is to provide clinicians with the skills to provide patient-centered care in order to individualize therapy and improve patient satisfaction, adherence and quality of life (QOL).

Faculty

Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Supervisor Nurse Practitioner
Henry Ford Health System
Division of Endocrinology, Diabetes and Bone Disorders
Detroit, Michigan


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Davida F. Kruger, MSN, APN-BC, BC-ADM
Advisory Boards: Abbott, Dexcom, Eli Lilly & Company, Intarcia, Janssen, Novo Nordisk, Sanofi Aventis,
Speakers Bureau: Abbott, AstraZeneca, BI Lilly, Dexcom, Insulet, Janssen, Lilly, Novo Nordisk, Valeritas,
Grants/Research Support Committees: Abbott, AstraZeneca, Dexcom, Eli Lilly, Hemsley Foundation, Lexicom, Novo Nordisk,
Stock: Dexcom

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 11, 2019 through April 11, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi US and Novo Nordisk do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by educational grants from Sanofi US and Novo Nordisk.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: April 11, 2019
Expires: April 11, 2020
1.0 hour to complete

Provided By

Target Audience

This educational initiative has been designed for family practice and primary care providers (PCPs) involved in the management of patients with diabetes.

Activity Description

A BioDigital Human on-demand simulation activity has been developed as a derivative of the live program content. Simulation decisions and feedback will be supported by evidence-based content and expert faculty explanation.

Learning Objectives

Upon completion of this educational activity, participants will be able to:

  • Articulate clinical strategies for the timely initiation and modification, and intensification of insulin therapy to achieve glycemic control
  • Explain novel strategies to optimize insulin therapy in clinical practice to improve glucose control, reduce risk of weight gain and hypoglycemia, and increase patient access, acceptance and adherence
  • Utilize a patient-centered approach to individualize therapy and appropriately and effectively transition patients to insulin and insulin combinations

Statement of Educational Need

Although practitioners know poor glycemic control puts their patients at increased risk for developing diabetes complications, many delay insulin therapy. This program has been developed to aid family practice clinicians, who are at the frontline of care for these individuals. It will examine the safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) data of newer basal insulin analogs as compared to older insulins. In addition, our faculty will review clinical data on combinations of basal insulin with rapid-acting insulin and GLP-1 receptor agonists and provide updates on newer follow-on insulin therapies. The ultimate goal is to provide clinicians with the skills to provide patient-centered care in order to individualize therapy and improve patient satisfaction, adherence and quality of life (QOL).

Faculty

Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Supervisor Nurse Practitioner
Henry Ford Health System
Division of Endocrinology, Diabetes and Bone Disorders
Detroit, Michigan


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Davida F. Kruger, MSN, APN-BC, BC-ADM
Advisory Boards: Abbott, Dexcom, Eli Lilly & Company, Intarcia, Janssen, Novo Nordisk, Sanofi Aventis,
Speakers Bureau: Abbott, AstraZeneca, BI Lilly, Dexcom, Insulet, Janssen, Lilly, Novo Nordisk, Valeritas,
Grants/Research Support Committees: Abbott, AstraZeneca, Dexcom, Eli Lilly, Hemsley Foundation, Lexicom, Novo Nordisk,
Stock: Dexcom

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 11, 2019 through April 11, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi US and Novo Nordisk do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by educational grants from Sanofi US and Novo Nordisk.

1.25 CME / CNE
Vindico
Applying New Guidelines, Imaging, and Insights on Extending the Treatment Window in Acute Ischemic Stroke

Applying New Guidelines, Imaging, and Insights on Extending the Treatment Window in Acute Ischemic Stroke

Start

Activity Details

Free CME/CNE
1.25 AMA PRA Category 1 Credit(s)
1.25 contact hours
Released: April 5, 2019
Expires: April 4, 2020
1.25 hours to complete

Accredited By

This continuing education activity is provided by Vindico Medical Education.

Target Audience

The intended audience for this activity is neurologists, cardiologists, nurses, and other health care professionals involved in the treatment of patients with acute ischemic stroke.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

Physicians

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Incorporate the use of image-guided treatment to improve outcomes in patients with AIS.

Nurses

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Assess the use of image-guided treatment to improve outcomes in patients with AIS.

Activity Description

Based on the success of several new clinical trials, the American Heart Association/American Stroke Association released updated stroke treatment guidelines in 2018. The guidelines address prehospital management, diagnosis, and treatment. Key revisions include extending the treatment window for mechanical thrombectomy in eligible patients and broadening the number of patients who qualify for thrombolysis. Advances in imaging techniques and technology have improved the overall management of acute ischemic stroke (AIS), and physicians must keep apprised of how to best incorporate these findings into practice to improve patient care. This CME/CNE activity will review the revised guidelines for patients with suspected AIS and patients who present outside the recommended time limit for thrombolysis, as well as the use of image-guided treatment to improve outcomes.

Faculty

Activity Chair

Philip B. Gorelick, MD, MPH
Adjunct Professor, Davee Department of Neurology
Division of Vascular Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures
No relevant financial relationships to disclose.


Faculty

Gregory W. Albers, MD
Director, Stanford Stroke Center
Coyote Foundation Professor of Neurology and
Neurological Sciences
Stanford University Medical Center
Stanford, CA
Disclosures
Consulting Fee: Genentech, iSchemaView, Medtronic
Ownership Interest: iSchemaView


Edward C. Jauch, MD, MS
Chief of System Research
Mission Research Institute/Mission Health
Asheville, NC
Disclosures
Consulting Fee: Biogen


Christopher A. Lewandowski, MD
Executive Vice Chair, Department of Emergency Medicine
Henry Ford Health System
Clinical Professor of Emergency Medicine, Wayne State University
Detroit, MI
Disclosures
Consulting Fee: Shire
Research Funding: NIH


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Maria Gannett, MSN, CRNP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center (ANCC) Commission on Accreditation’s Standards for Commercial Support, all CME/CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME/CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education, LLC, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide 1.25 contact hours for nurses.

This enduring material is approved for 1 year from the date of original release, April 5, 2019 to April 4, 2020.

Instructions for Receiving Credit

To participate in this CME/CNE activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Learner-Paced Continuing Nursing Education Contact Hour Certificate.

MIPS Qualifying Activity

Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Contact Information for Questions about the Activity

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME/CNE Questions?
Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CNE
1.25 AMA PRA Category 1 Credit(s)
1.25 contact hours
Released: April 5, 2019
Expires: April 4, 2020
1.25 hours to complete

Accredited By

This continuing education activity is provided by Vindico Medical Education.

Target Audience

The intended audience for this activity is neurologists, cardiologists, nurses, and other health care professionals involved in the treatment of patients with acute ischemic stroke.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

Physicians

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Incorporate the use of image-guided treatment to improve outcomes in patients with AIS.

Nurses

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Assess the use of image-guided treatment to improve outcomes in patients with AIS.

Activity Description

Based on the success of several new clinical trials, the American Heart Association/American Stroke Association released updated stroke treatment guidelines in 2018. The guidelines address prehospital management, diagnosis, and treatment. Key revisions include extending the treatment window for mechanical thrombectomy in eligible patients and broadening the number of patients who qualify for thrombolysis. Advances in imaging techniques and technology have improved the overall management of acute ischemic stroke (AIS), and physicians must keep apprised of how to best incorporate these findings into practice to improve patient care. This CME/CNE activity will review the revised guidelines for patients with suspected AIS and patients who present outside the recommended time limit for thrombolysis, as well as the use of image-guided treatment to improve outcomes.

Faculty

Activity Chair

Philip B. Gorelick, MD, MPH
Adjunct Professor, Davee Department of Neurology
Division of Vascular Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures
No relevant financial relationships to disclose.


Faculty

Gregory W. Albers, MD
Director, Stanford Stroke Center
Coyote Foundation Professor of Neurology and
Neurological Sciences
Stanford University Medical Center
Stanford, CA
Disclosures
Consulting Fee: Genentech, iSchemaView, Medtronic
Ownership Interest: iSchemaView


Edward C. Jauch, MD, MS
Chief of System Research
Mission Research Institute/Mission Health
Asheville, NC
Disclosures
Consulting Fee: Biogen


Christopher A. Lewandowski, MD
Executive Vice Chair, Department of Emergency Medicine
Henry Ford Health System
Clinical Professor of Emergency Medicine, Wayne State University
Detroit, MI
Disclosures
Consulting Fee: Shire
Research Funding: NIH


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Maria Gannett, MSN, CRNP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center (ANCC) Commission on Accreditation’s Standards for Commercial Support, all CME/CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME/CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education, LLC, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide 1.25 contact hours for nurses.

This enduring material is approved for 1 year from the date of original release, April 5, 2019 to April 4, 2020.

Instructions for Receiving Credit

To participate in this CME/CNE activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Learner-Paced Continuing Nursing Education Contact Hour Certificate.

MIPS Qualifying Activity

Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Contact Information for Questions about the Activity

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME/CNE Questions?
Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
Integrity Continuing Education, Inc.
Strategies to Provide Individualized Treatment in Moderate-to-Severe Atopic Dermatitis

Strategies to Provide Individualized Treatment in Moderate-to-Severe Atopic Dermatitis

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: December 7, 2018
Expires: December 7, 2019
45 minutes to complete

Provided By

Target Audience

This educational initiative has been designed for dermatologists, allergists, primary care physicians, nurse practitioners, and physician assistants involved in the management of atopic dermatitis (AD).

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Utilize updated criteria and guidelines to accurately diagnose AD and assess severity
  • Describe the limitations of currently available therapies in addressing underlying AD pathophysiology
  • Evaluate recent clinical evidence on the utility of approved and emerging biologic agents to address the underlying pathophysiology of AD
  • Discuss strategies that will improve patient satisfaction with treatment and reduce the burden of comorbidities

Activity Description

Patients with atopic dermatitis (AD) are sub-optimally managed in current clinical practice and hence report a poor quality of life and high burden from their disease and comorbidities. There remains an unmet need for effective therapies that not only relieve distressing symptoms of AD, but also improve long-term outcomes for patients. An improved understanding of the pathogenesis of AD has led to the development of biologic agents, including dupilumab, which are known to target the underlying pathophysiology of AD. Despite this progress, AD continues to impose a huge healthcare burden due to knowledge and competence deficits among healthcare professionals.

There is a need to improve the diagnosis, assessment of severity, treatment, and management of AD to enable improved outcomes and quality of life among patients. This program will include topics that will improve healthcare professionals’ ability to accurately diagnose and recognize AD among patients presenting with eczema by informing participants about updated diagnostic criteria and assessment scores to differentially diagnose AD and its severity. Discussions on updated guidelines, recommendations, and recent clinical evidence to inform treatment decisions to alleviate the symptom burden of AD will be included and evaluated. Clinicians will also learn strategies to improve communication and adherence to treatment, and address the comorbidities of AD.

Faculty

Amy S. Paller, MS, MD
Chair, Department of Dermatology
Director, Northwestern University Skin Disease Research Center
Walter J. Hamlin Professor of Dermatology
Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois


Jonathan M. Spergel, MD, PhD
Professor of Pediatrics
Chief, Allergy Section
Stuart E. Starr Endowed Chair of Pediatrics
Director, Center for Pediatric Eosinophilic Disease
Director, FARE Center of Excellence
The Children’s Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Amy S. Paller, MS, MD
Consulting Fees: AbbVie, Asana, Dermavant, Dermira, Galderma, Eli Lilly, Forte, Leo, Matrisys, Menlo, Morphosys/Galapagos, Novartis Pharmaceuticals Corporation, Pfizer, Promius, Sanofi Genzyme and Regeneron Pharmaceuticals
Contracted Research: AbbVie, Anaptysbio, Eli Lilly, Galderma, Incyte, Leo, Janssen, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals

Jonathan M. Spergel, MD, PhD
Royalty: Up-To-Date
Consulting Fees: Regeneron Pharmaceuticals, Shire
Contracted Research: AbbVie, Regeneron Pharmaceuticals

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of December 7, 2018 through December 7, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions about the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: December 7, 2018
Expires: December 7, 2019
45 minutes to complete

Provided By

Target Audience

This educational initiative has been designed for dermatologists, allergists, primary care physicians, nurse practitioners, and physician assistants involved in the management of atopic dermatitis (AD).

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Utilize updated criteria and guidelines to accurately diagnose AD and assess severity
  • Describe the limitations of currently available therapies in addressing underlying AD pathophysiology
  • Evaluate recent clinical evidence on the utility of approved and emerging biologic agents to address the underlying pathophysiology of AD
  • Discuss strategies that will improve patient satisfaction with treatment and reduce the burden of comorbidities

Activity Description

Patients with atopic dermatitis (AD) are sub-optimally managed in current clinical practice and hence report a poor quality of life and high burden from their disease and comorbidities. There remains an unmet need for effective therapies that not only relieve distressing symptoms of AD, but also improve long-term outcomes for patients. An improved understanding of the pathogenesis of AD has led to the development of biologic agents, including dupilumab, which are known to target the underlying pathophysiology of AD. Despite this progress, AD continues to impose a huge healthcare burden due to knowledge and competence deficits among healthcare professionals.

There is a need to improve the diagnosis, assessment of severity, treatment, and management of AD to enable improved outcomes and quality of life among patients. This program will include topics that will improve healthcare professionals’ ability to accurately diagnose and recognize AD among patients presenting with eczema by informing participants about updated diagnostic criteria and assessment scores to differentially diagnose AD and its severity. Discussions on updated guidelines, recommendations, and recent clinical evidence to inform treatment decisions to alleviate the symptom burden of AD will be included and evaluated. Clinicians will also learn strategies to improve communication and adherence to treatment, and address the comorbidities of AD.

Faculty

Amy S. Paller, MS, MD
Chair, Department of Dermatology
Director, Northwestern University Skin Disease Research Center
Walter J. Hamlin Professor of Dermatology
Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois


Jonathan M. Spergel, MD, PhD
Professor of Pediatrics
Chief, Allergy Section
Stuart E. Starr Endowed Chair of Pediatrics
Director, Center for Pediatric Eosinophilic Disease
Director, FARE Center of Excellence
The Children’s Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Amy S. Paller, MS, MD
Consulting Fees: AbbVie, Asana, Dermavant, Dermira, Galderma, Eli Lilly, Forte, Leo, Matrisys, Menlo, Morphosys/Galapagos, Novartis Pharmaceuticals Corporation, Pfizer, Promius, Sanofi Genzyme and Regeneron Pharmaceuticals
Contracted Research: AbbVie, Anaptysbio, Eli Lilly, Galderma, Incyte, Leo, Janssen, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals

Jonathan M. Spergel, MD, PhD
Royalty: Up-To-Date
Consulting Fees: Regeneron Pharmaceuticals, Shire
Contracted Research: AbbVie, Regeneron Pharmaceuticals

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of December 7, 2018 through December 7, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions about the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

1.50 CME
Global Education Group
The Changing Landscape of IBD: Emerging Concepts in Patient Management

The Changing Landscape of IBD: Emerging Concepts in Patient Management

Start

A Multimedia Educational eHealth Source™

Activity Details

Free CME
1.5 AMA PRA Category 1 Credits
Released: January 17, 2019
Expires: January 17, 2020
1 hour, 30 mins to complete

Jointly Provided by

Target Audience

This activity is intended for clinical gastroenterologists and specialist NP/PAs involved in the treatment of patients with inflammatory bowel disease (IBD).

Learning Objectives

  • Evaluate disease risk and identify individuals who are likely to benefit from biologic or targeted synthetic therapy
  • Tailor management regimens for patients with inflammatory bowel disease (IBD) using a treat-to-target approach that reflects disease severity, treatment goals, therapeutic responses, and patient preferences
  • Partner with patients to provide IBD disease state education, promote shared clinical decision-making, encourage self-management efforts, and personalize long-term care
  • Discuss the cytokine networks underlying IBD pathophysiology, with a focus on newer mechanisms of action
  • Review mechanisms of current and novel non–tumor necrosis factor biologic and targeted synthetic therapies for the treatment of IBD

Activity Description

This activity presents an in-depth review of IBD patient care in moderate to severe disease, including immunopathogenesis of IBD, existing management options, shared decision-making, and investigational targeted therapies, via text and concise video commentaries provided by noted IBD experts

Statement of Educational Need

In the past 2 decades, the introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of the inflammatory bowel diseases (IBDs)—ulcerative colitis and Crohn’s disease. Current biologic therapy with tumor necrosis factor inhibitors and anti-integrins has improved the treatment of IBD flares and maintenance of clinical remission. These agents are, however, limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the pathogenesis and treatment of IBD are complex and variable, there is a need to better understand the underlying pathogenic mechanisms and develop drug therapies to target these mechanisms.1

Geared to the needs of gastroenterologists, this IBD eHealth program includes an update on patient assessment and treat-to-target goals, as well as a review of best practices in shared decision-making in treatment decisions for induction and maintenance of remission. In addition, the immunopathogenesis of IBD is discussed in the context of current and emerging targeted therapies for moderate to severe disease.

Reference

1. Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127-142.

Agenda

  • Chapter 1: Assessment Strategies and Treatment Goals in IBD
  • Chapter 2: Best Practices in Tailoring Treatment of Moderate and Severe IBD
  • Chapter 3: Evolving Concepts in IBD Pathophysiology
  • Chapter 4: Targeted Mechanism-Based Therapies for IBD on the Horizon

Faculty

Raymond K. Cross, MD, MS
Professor of Medicine
Director, Inflammatory Bowel Disease Program
University of Maryland School of Medicine
Co-Director, Digestive Health Center
University of Maryland Medical Center
Baltimore, MD


Gary R. Lichtenstein, MD
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Raymond K. Cross, MD, MS
  • Consultant/Independent Contractor: AbbVie Inc, Janssen, LabCorp, Pfizer, UCB
  • Grant/Research Support: AbbVie Inc

Gary R. Lichtenstein, MD
  • Consultant: AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Luitpold Pharmaceuticals, Inc., Merck & Co., Pfizer Inc., Prometheus Laboratories Inc., Romark, L.C., Salix Pharmaceuticals, Inc., Shire Plc, Takeda Pharmaceuticals North America, Inc., UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Grant/Research Support: Celgene Corporation, Janssen Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Shire Plc, UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastroenterology and Hepatology (Gastro-Hep Communications, Inc.), Luitpold Pharmaceuticals, Inc., McMahon Publishing, Merck & Co., Romark, L.C., Springer Science+Business Media, UpToDate®
  • Other/Royalty: Eli Lilly and Company (Data and Safety Monitoring Board), Janssen Pharmaceuticals, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), Pfizer Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), SLACK, Incorporated (Book Royalty), Takeda Pharmaceuticals North America, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania)

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Lindsay Borvansky, Andrea Funk, Liddy Knight, Kayla Messer, Jim Kappler, PhD, Julia Muino.

Designation of Credit

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the post-test and program evaluation. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

A Multimedia Educational eHealth Source™

Activity Details

Free CME
1.5 AMA PRA Category 1 Credits
Released: January 17, 2019
Expires: January 17, 2020
1 hour, 30 mins to complete

Jointly Provided by

Target Audience

This activity is intended for clinical gastroenterologists and specialist NP/PAs involved in the treatment of patients with inflammatory bowel disease (IBD).

Learning Objectives

  • Evaluate disease risk and identify individuals who are likely to benefit from biologic or targeted synthetic therapy
  • Tailor management regimens for patients with inflammatory bowel disease (IBD) using a treat-to-target approach that reflects disease severity, treatment goals, therapeutic responses, and patient preferences
  • Partner with patients to provide IBD disease state education, promote shared clinical decision-making, encourage self-management efforts, and personalize long-term care
  • Discuss the cytokine networks underlying IBD pathophysiology, with a focus on newer mechanisms of action
  • Review mechanisms of current and novel non–tumor necrosis factor biologic and targeted synthetic therapies for the treatment of IBD

Activity Description

This activity presents an in-depth review of IBD patient care in moderate to severe disease, including immunopathogenesis of IBD, existing management options, shared decision-making, and investigational targeted therapies, via text and concise video commentaries provided by noted IBD experts

Statement of Educational Need

In the past 2 decades, the introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of the inflammatory bowel diseases (IBDs)—ulcerative colitis and Crohn’s disease. Current biologic therapy with tumor necrosis factor inhibitors and anti-integrins has improved the treatment of IBD flares and maintenance of clinical remission. These agents are, however, limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the pathogenesis and treatment of IBD are complex and variable, there is a need to better understand the underlying pathogenic mechanisms and develop drug therapies to target these mechanisms.1

Geared to the needs of gastroenterologists, this IBD eHealth program includes an update on patient assessment and treat-to-target goals, as well as a review of best practices in shared decision-making in treatment decisions for induction and maintenance of remission. In addition, the immunopathogenesis of IBD is discussed in the context of current and emerging targeted therapies for moderate to severe disease.

Reference

1. Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127-142.

Agenda

  • Chapter 1: Assessment Strategies and Treatment Goals in IBD
  • Chapter 2: Best Practices in Tailoring Treatment of Moderate and Severe IBD
  • Chapter 3: Evolving Concepts in IBD Pathophysiology
  • Chapter 4: Targeted Mechanism-Based Therapies for IBD on the Horizon

Faculty

Raymond K. Cross, MD, MS
Professor of Medicine
Director, Inflammatory Bowel Disease Program
University of Maryland School of Medicine
Co-Director, Digestive Health Center
University of Maryland Medical Center
Baltimore, MD


Gary R. Lichtenstein, MD
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Raymond K. Cross, MD, MS
  • Consultant/Independent Contractor: AbbVie Inc, Janssen, LabCorp, Pfizer, UCB
  • Grant/Research Support: AbbVie Inc

Gary R. Lichtenstein, MD
  • Consultant: AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Luitpold Pharmaceuticals, Inc., Merck & Co., Pfizer Inc., Prometheus Laboratories Inc., Romark, L.C., Salix Pharmaceuticals, Inc., Shire Plc, Takeda Pharmaceuticals North America, Inc., UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Grant/Research Support: Celgene Corporation, Janssen Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Shire Plc, UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastroenterology and Hepatology (Gastro-Hep Communications, Inc.), Luitpold Pharmaceuticals, Inc., McMahon Publishing, Merck & Co., Romark, L.C., Springer Science+Business Media, UpToDate®
  • Other/Royalty: Eli Lilly and Company (Data and Safety Monitoring Board), Janssen Pharmaceuticals, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), Pfizer Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), SLACK, Incorporated (Book Royalty), Takeda Pharmaceuticals North America, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania)

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Lindsay Borvansky, Andrea Funk, Liddy Knight, Kayla Messer, Jim Kappler, PhD, Julia Muino.

Designation of Credit

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the post-test and program evaluation. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
American Gastroenterological Association
Optimizing Management in IBD: Challenging Cases

Optimizing Management in IBD: Challenging Cases

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: December 26, 2018
Expires: December 25, 2019
0.75 hour to complete

Accredited By

The American Gastroenterological Association (AGA) Institute

Target Audience

Gastroenterologists and gastroenterology NPs and PAs

Learning Objectives

  • Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
  • Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity
  • Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
  • Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making

Faculty

Gil Y. Melmed, MD, MS (Chair)
Co-Director, Clinical Inflammatory Bowel Disease
Division of Gastroenterology/Department of Medicine
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA


Adam S. Cheifetz, MD
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA


Gary R. Lichtenstein, MD, FACP, FACG, AGAF
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA

Disclosure of Conflicts of Interest

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda (Consulting Fees); Pfizer (Research).
  • Adam S. Cheifetz, MD, has affiliations with AbbVie, Arena, Ferring, Janssen, Pfizer, Samsung, Takeda (Consulting Fees); Miraca (Grant/Research Support).
  • Gary R. Lichtenstein, MD, FACP, FACG, AGAF, has affiliations with Abbott Corporation/AbbVie, Celgene, CellCeutrix, Ferring, Gilead, Janssen Orthobiotech, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals, Shire, Takeda, UCB (Consulting Fees); Celgene, Janssen Orthobiotech, Salix Pharmaceuticals, Shire, UCB (Research); Luitpold/American Regent, Merck, Romark (Other Financial Benefit).  

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

AGA Institute

  • Monique Dyson, has no affiliations with commercial interests to disclose.
  • Sandra Amos, has no affiliations with commercial interests to disclose.

Physician Continuing Medical Education

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. After the successful completion of A Pathway to Evidence-Based Management of IBD and Optimizing Management in IBD: Challenging Cases, learners will receive an AGA-branded certificate recognizing their mastery of IBD management.



COMPLETE THE EVALUATION FORM AND GET A CHANCE TO WIN A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.
 
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.


Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: December 26, 2018
Expires: December 25, 2019
0.75 hour to complete

Accredited By

The American Gastroenterological Association (AGA) Institute

Target Audience

Gastroenterologists and gastroenterology NPs and PAs

Learning Objectives

  • Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
  • Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity
  • Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
  • Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making

Faculty

Gil Y. Melmed, MD, MS (Chair)
Co-Director, Clinical Inflammatory Bowel Disease
Division of Gastroenterology/Department of Medicine
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA


Adam S. Cheifetz, MD
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA


Gary R. Lichtenstein, MD, FACP, FACG, AGAF
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA

Disclosure of Conflicts of Interest

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda (Consulting Fees); Pfizer (Research).
  • Adam S. Cheifetz, MD, has affiliations with AbbVie, Arena, Ferring, Janssen, Pfizer, Samsung, Takeda (Consulting Fees); Miraca (Grant/Research Support).
  • Gary R. Lichtenstein, MD, FACP, FACG, AGAF, has affiliations with Abbott Corporation/AbbVie, Celgene, CellCeutrix, Ferring, Gilead, Janssen Orthobiotech, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals, Shire, Takeda, UCB (Consulting Fees); Celgene, Janssen Orthobiotech, Salix Pharmaceuticals, Shire, UCB (Research); Luitpold/American Regent, Merck, Romark (Other Financial Benefit).  

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

AGA Institute

  • Monique Dyson, has no affiliations with commercial interests to disclose.
  • Sandra Amos, has no affiliations with commercial interests to disclose.

Physician Continuing Medical Education

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. After the successful completion of A Pathway to Evidence-Based Management of IBD and Optimizing Management in IBD: Challenging Cases, learners will receive an AGA-branded certificate recognizing their mastery of IBD management.



COMPLETE THE EVALUATION FORM AND GET A CHANCE TO WIN A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.
 
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.


Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.75 CME / MOC
The France Foundation
The Lupus Hub: Primary Care’s Pivotal Role in SLE

The Lupus Hub: Primary Care’s Pivotal Role in SLE

Start

Activity Details

Free CME/MOC
.75 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: December 18, 2018
Expires: December 17, 2019
45 minutes to complete

Accredited By

Target Audience

This educational initiative is intended for primary care clinicians who care for adult patients with SLE.

Learning Objectives

  1. Describe key evidence-based strategies for diagnosing SLE.
  2. Utilize effective strategies to assess and co-manage patients with SLE over time.
  3. Summarize key aspects of established treatments for SLE.
  4. Monitor the patient for treatment side effects.
  5. Formulate a plan for communication with patients about SLE and its treatment, including methods for facilitating treatment adherence.

Activity Description

Autoimmune diseases are difficult to diagnose. Lupus, in particular, is complicated as its symptoms are common to a variety of other conditions. Diagnosing lupus with any degree of accuracy can be challenging and costly. This activity will orient the primary care provider on how to accurately diagnose systemic lupus erythematosus (SLE), further providing guidance on management strategies and doctor-patient communication, specifically with the goal of increasing treatment adherence in patients.

Agenda

  1. Recognizing SLE: Primary Care Approach to Diagnostic Criteria
    How to recognize the condition based on ACR criteria.
  2. Assessing a Moving Target: SLE Evaluation Over Time
    Signs of disease progression; when to recommend further evaluation.
  3. Answering the “Whats” and “Whens” of Management
    Understanding treatment options, facilitating specialist consultation, and monitoring for treatment side effects.
  4. Keeping the Lines Open: Practical Strategies for Communication and Facilitating Adherence
    What are effective communication techniques (eg, AHRQ’s “Teach Back” method, particular phrasing for adherence-related questions, encouraging patient-generated questions) that can address sensitive or challenging issues? Applying practical patient-centered approaches as a means to facilitate treatment adherence.

Faculty

Louis Kuritzky, MD
Louis Kuritzky, MD
Content Creator and Activity Presenter
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida, Gainesville
Gainesville, Florida

Disclosure:
Louis Kurtizky, MD, has no relevant financial relationships to disclose.


Daniel J. Wallace, MD, FACP, MACR
Daniel J. Wallace, MD, FACP, MACR
Content Creator
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California

Disclosure:
Daniel J. Wallace, MD, FACP, MACR, has served as an advisor for Amgen, EMD Serono, Celgene, Merck, Lilly.


MOC Reviewer

Richard Sadovsky, MD, MS
Associate Professor of Family Medicine
SUNY-Downstate Medical center

Disclosure:
Richard Sadovsky, MD, has no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, The France Foundation seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The France Foundation is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The France Foundation does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/MOC
.75 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: December 18, 2018
Expires: December 17, 2019
45 minutes to complete

Accredited By

Target Audience

This educational initiative is intended for primary care clinicians who care for adult patients with SLE.

Learning Objectives

  1. Describe key evidence-based strategies for diagnosing SLE.
  2. Utilize effective strategies to assess and co-manage patients with SLE over time.
  3. Summarize key aspects of established treatments for SLE.
  4. Monitor the patient for treatment side effects.
  5. Formulate a plan for communication with patients about SLE and its treatment, including methods for facilitating treatment adherence.

Activity Description

Autoimmune diseases are difficult to diagnose. Lupus, in particular, is complicated as its symptoms are common to a variety of other conditions. Diagnosing lupus with any degree of accuracy can be challenging and costly. This activity will orient the primary care provider on how to accurately diagnose systemic lupus erythematosus (SLE), further providing guidance on management strategies and doctor-patient communication, specifically with the goal of increasing treatment adherence in patients.

Agenda

  1. Recognizing SLE: Primary Care Approach to Diagnostic Criteria
    How to recognize the condition based on ACR criteria.
  2. Assessing a Moving Target: SLE Evaluation Over Time
    Signs of disease progression; when to recommend further evaluation.
  3. Answering the “Whats” and “Whens” of Management
    Understanding treatment options, facilitating specialist consultation, and monitoring for treatment side effects.
  4. Keeping the Lines Open: Practical Strategies for Communication and Facilitating Adherence
    What are effective communication techniques (eg, AHRQ’s “Teach Back” method, particular phrasing for adherence-related questions, encouraging patient-generated questions) that can address sensitive or challenging issues? Applying practical patient-centered approaches as a means to facilitate treatment adherence.

Faculty

Louis Kuritzky, MD
Louis Kuritzky, MD
Content Creator and Activity Presenter
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida, Gainesville
Gainesville, Florida

Disclosure:
Louis Kurtizky, MD, has no relevant financial relationships to disclose.


Daniel J. Wallace, MD, FACP, MACR
Daniel J. Wallace, MD, FACP, MACR
Content Creator
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California

Disclosure:
Daniel J. Wallace, MD, FACP, MACR, has served as an advisor for Amgen, EMD Serono, Celgene, Merck, Lilly.


MOC Reviewer

Richard Sadovsky, MD, MS
Associate Professor of Family Medicine
SUNY-Downstate Medical center

Disclosure:
Richard Sadovsky, MD, has no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, The France Foundation seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The France Foundation is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The France Foundation does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME
Global Education Group
Evolving Management Strategies for Moderate-to-Severe Atopic Dermatitis: Looking Beyond Barriers to Optimize Therapy

Evolving Management Strategies for Moderate-to-Severe Atopic Dermatitis: Looking Beyond Barriers to Optimize Therapy

Start
Free CME
1.0 AMA PRA Category 1 Credit
Released: December 14, 2018
Expires: December 13, 2019
60 minutes to complete

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with atopic dermatitis.

Statement of Need

Atopic dermatitis is a common, chronic inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.1,2 The disease-related physical and biopsychosocial burdens of atopic dermatitis can have a substantial effect on patients’ quality of life, particularly in those with moderate-to-severe disease.3,4 A better understanding of atopic dermatitis etiology has supported the development of new approaches to disease characterization and targeted therapies.5,6 As a result, the first biologic therapy is now available to treat patients with moderate-to-severe disease, and several other therapies are in late-stage clinical development.7-10 With novel therapies emerging for patients with difficult-to-treat atopic dermatitis, dermatologists will benefit from updates on the latest clinical trial data and practical recommendations on how to translate those results into daily clinical decision-making. In this Evidence-Based Best Practices™ program, internationally recognized experts will review the latest published evidence with a goal of providing recommendations to enhance overall patient outcomes. The expert faculty panel will discuss the pathophysiologic underpinnings of atopic dermatitis, share best practices related to comprehensive patient evaluations, and relay their own clinical experience in managing patients with moderate-to-severe disease.

References

  • Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
  • Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
  • Whiteley J, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1-7. [Epub ahead of print].
  • Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
  • Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
  • Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  • Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  • de Bruin-Weller M, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-1101.
  • Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;5(6):1477-1487.
  • Cotter DG, et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3S1):S53-S62.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss atopic dermatitis pathophysiology, including clinically relevant molecular and cellular targets
  • Assess patients with atopic dermatitis longitudinally for uncontrolled symptoms, disease flares, comorbidities, and clinical responses to their current treatment regimens
  • Describe the clinical profiles of targeted biologic therapies for the treatment of moderate-to-severe atopic dermatitis
  • Optimize treatment regimens for patients with moderate-to-severe atopic dermatitis to reduce symptomatology, address comorbidities, maximize health-related quality of life, and minimize treatment-related side effects
  • Educate patients and caregivers to improve their understanding of atopic dermatitis to promote shared decision-making and treatment adherence

Faculty

Marjolein de Bruin-Weller, MD, PhD
Head, National Expertise Center for Atopic Dermatitis
Department of Dermatology/Allergology
University Medical Center Utrecht
Utrecht, The Netherlands



Eric L. Simpson, MD, MCR
Professor of Dermatology
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, Oregon, USA



Andreas Wollenberg, MD, PhD
Professor
Department of Dermatology and Allergy
Ludwig-Maximilian University of Munich
Munich, Germany


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Marjolein de Bruin-Weller, MD, PhD

  • Consultant/Advisor: AbbVie Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
  • Grant/Research Support: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.

Eric L. Simpson, MD, MCR

  • Consultant/Advisor: AbbVie Inc., Eli Lilly and Company, Galderma Laboratories, L.P., LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.
  • Grant/Research Support: Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc.

Andreas Wollenberg, MD, PhD

  • Consultant/Advisor: Almirall Limited, Beiersdorf AG, Galderma S.A., LEO Pharma Inc., L’Oréal S.A., MedImmune, LLC, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.
  • Grant/Research Support: Beiersdorf AG, LEO Pharma Inc.
  • Speakers Bureau: Almirall Limited, Anacor Pharmaceuticals, Inc., Astellas Pharma Europe Ltd, Beierdsorf AG, Bioderma Laboratoire Dermatologique, Celgene Corporation, Chugai Pharmaceutical Co., Ltd., Galderma S.A., Hans Karrer GMBH, LEO Pharma Inc., L’Oréal S.A., Meda AB, MedImmune, LLC, Merck Sharp & Dohme Corp., Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Stacey Ullman, MHS
Nothing to disclose

Ashley Marostica, RN, MSN
Nothing to disclose

Lindsay Borvansky
Nothing to disclose

Andrea Funk
Nothing to disclose

Liddy Knight
Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Free CME
1.0 AMA PRA Category 1 Credit
Released: December 14, 2018
Expires: December 13, 2019
60 minutes to complete

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with atopic dermatitis.

Statement of Need

Atopic dermatitis is a common, chronic inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.1,2 The disease-related physical and biopsychosocial burdens of atopic dermatitis can have a substantial effect on patients’ quality of life, particularly in those with moderate-to-severe disease.3,4 A better understanding of atopic dermatitis etiology has supported the development of new approaches to disease characterization and targeted therapies.5,6 As a result, the first biologic therapy is now available to treat patients with moderate-to-severe disease, and several other therapies are in late-stage clinical development.7-10 With novel therapies emerging for patients with difficult-to-treat atopic dermatitis, dermatologists will benefit from updates on the latest clinical trial data and practical recommendations on how to translate those results into daily clinical decision-making. In this Evidence-Based Best Practices™ program, internationally recognized experts will review the latest published evidence with a goal of providing recommendations to enhance overall patient outcomes. The expert faculty panel will discuss the pathophysiologic underpinnings of atopic dermatitis, share best practices related to comprehensive patient evaluations, and relay their own clinical experience in managing patients with moderate-to-severe disease.

References

  • Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
  • Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
  • Whiteley J, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1-7. [Epub ahead of print].
  • Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
  • Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
  • Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  • Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  • de Bruin-Weller M, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-1101.
  • Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;5(6):1477-1487.
  • Cotter DG, et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3S1):S53-S62.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss atopic dermatitis pathophysiology, including clinically relevant molecular and cellular targets
  • Assess patients with atopic dermatitis longitudinally for uncontrolled symptoms, disease flares, comorbidities, and clinical responses to their current treatment regimens
  • Describe the clinical profiles of targeted biologic therapies for the treatment of moderate-to-severe atopic dermatitis
  • Optimize treatment regimens for patients with moderate-to-severe atopic dermatitis to reduce symptomatology, address comorbidities, maximize health-related quality of life, and minimize treatment-related side effects
  • Educate patients and caregivers to improve their understanding of atopic dermatitis to promote shared decision-making and treatment adherence

Faculty

Marjolein de Bruin-Weller, MD, PhD
Head, National Expertise Center for Atopic Dermatitis
Department of Dermatology/Allergology
University Medical Center Utrecht
Utrecht, The Netherlands



Eric L. Simpson, MD, MCR
Professor of Dermatology
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, Oregon, USA



Andreas Wollenberg, MD, PhD
Professor
Department of Dermatology and Allergy
Ludwig-Maximilian University of Munich
Munich, Germany


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Marjolein de Bruin-Weller, MD, PhD

  • Consultant/Advisor: AbbVie Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
  • Grant/Research Support: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.

Eric L. Simpson, MD, MCR

  • Consultant/Advisor: AbbVie Inc., Eli Lilly and Company, Galderma Laboratories, L.P., LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.
  • Grant/Research Support: Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc.

Andreas Wollenberg, MD, PhD

  • Consultant/Advisor: Almirall Limited, Beiersdorf AG, Galderma S.A., LEO Pharma Inc., L’Oréal S.A., MedImmune, LLC, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.
  • Grant/Research Support: Beiersdorf AG, LEO Pharma Inc.
  • Speakers Bureau: Almirall Limited, Anacor Pharmaceuticals, Inc., Astellas Pharma Europe Ltd, Beierdsorf AG, Bioderma Laboratoire Dermatologique, Celgene Corporation, Chugai Pharmaceutical Co., Ltd., Galderma S.A., Hans Karrer GMBH, LEO Pharma Inc., L’Oréal S.A., Meda AB, MedImmune, LLC, Merck Sharp & Dohme Corp., Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Stacey Ullman, MHS
Nothing to disclose

Ashley Marostica, RN, MSN
Nothing to disclose

Lindsay Borvansky
Nothing to disclose

Andrea Funk
Nothing to disclose

Liddy Knight
Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME
National Jewish Health
HIV Curbside Consults, Volume III: Treatment of Patients with HIV/TB Coinfection

HIV Curbside Consults, Volume III: Treatment of Patients with HIV/TB Coinfection

Start
Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: December 14, 2018
Expires: December 13, 2019
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Educational Partner:

Supporter Statement

This activity is supported by an educational grant from ViiV Healthcare.

Target Audience

The intended audience for the activity is infectious disease specialists and other health care professionals involved in the treatment of patients with HIV.

Learning Objectives

Upon successful completion of this activity, participants should be better able to select HIV treatment based on clinical profile, propensity for resistance, as well as patient comorbidities and/or co-infections.

Overview

In this case-based video, Grace A. McComsey, MD, FIDSA, and Paul E. Sax, MD, discuss the management of an older HIV-positive man admitted with weight loss, abdominal pain, and fever.

Activity Co-Chairs

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University School of Medicine
Co-Director, HIV/HCV Treatment and Research Program 
Providence Hospital
Washington, DC


Paul E. Sax, MD
Clinical Director, Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA


Faculty

Grace A. McComsey, MD, FIDSA
Associate Chief Scientific Officer, University Hospitals Health System
Director, UH Clinical Research Center and the Dahms Clinical Research Unit
John Kennell Endowed Chair
Chief, Pediatric Infectious Diseases
Rheumatology Professor of Pediatrics and Medicine
Case Western Reserve University
Cleveland, OH


External Reviewer

Lisa Hightow-Weidman, MD, MPH

Accreditation

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release December 14, 2018 to December 13, 2019.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentation, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, National Jewish Health will issue an AMA PRA Category 1 Credit(s)™ certificate.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Planning Committee and Faculty report the following relationship(s):
Richard A. Elion, MD
Consulting Fee: Gilead, ViiV 
Speakers Bureau: Gilead, Janssen 
Contracted Research: Gilead, Proteus

Grace A. McComsey, MD, FIDSA
Consulting Fee: Bristol-Myers Squibb, Gilead, ICON, ViiV

Paul E. Sax, MD
Consulting Fee: AbbVie, Bristol-Myers Squibb, Gilead, GlaxoSmithKline/ViiV, Janssen, Merck
Contracted Research: (Paid to institution): Bristol-Myers Squibb, Gilead, GlaxoSmithKline/ViiV

External Reviewer reports the following relationship(s):
Lisa Hightow-Weidman, MD, MPH 
No relevant financial relationships to disclose.

National Jewish Health and Vindico Medical Education staff report the following relationship(s):
Betti Bandura
No relevant financial relationships to disclose.

Mandy Comeau 
No relevant financial relationships to disclose.

Stephanie Corder, ND, RN, CHCP
No relevant financial relationships to disclose.

Jennifer Frederick, PharmD
No relevant financial relationships to disclose.

Lynda Lyons
No relevant financial relationships to disclose.

Signed disclosures are on file at National Jewish Health and Vindico Medical Education.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and National Jewish Health continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and National Jewish Health. Neither Vindico Medical Education, National Jewish Health, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: December 14, 2018
Expires: December 13, 2019
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Educational Partner:

Supporter Statement

This activity is supported by an educational grant from ViiV Healthcare.

Target Audience

The intended audience for the activity is infectious disease specialists and other health care professionals involved in the treatment of patients with HIV.

Learning Objectives

Upon successful completion of this activity, participants should be better able to select HIV treatment based on clinical profile, propensity for resistance, as well as patient comorbidities and/or co-infections.

Overview

In this case-based video, Grace A. McComsey, MD, FIDSA, and Paul E. Sax, MD, discuss the management of an older HIV-positive man admitted with weight loss, abdominal pain, and fever.

Activity Co-Chairs

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University School of Medicine
Co-Director, HIV/HCV Treatment and Research Program 
Providence Hospital
Washington, DC


Paul E. Sax, MD
Clinical Director, Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA


Faculty

Grace A. McComsey, MD, FIDSA
Associate Chief Scientific Officer, University Hospitals Health System
Director, UH Clinical Research Center and the Dahms Clinical Research Unit
John Kennell Endowed Chair
Chief, Pediatric Infectious Diseases
Rheumatology Professor of Pediatrics and Medicine
Case Western Reserve University
Cleveland, OH


External Reviewer

Lisa Hightow-Weidman, MD, MPH

Accreditation

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release December 14, 2018 to December 13, 2019.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentation, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, National Jewish Health will issue an AMA PRA Category 1 Credit(s)™ certificate.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Planning Committee and Faculty report the following relationship(s):
Richard A. Elion, MD
Consulting Fee: Gilead, ViiV 
Speakers Bureau: Gilead, Janssen 
Contracted Research: Gilead, Proteus

Grace A. McComsey, MD, FIDSA
Consulting Fee: Bristol-Myers Squibb, Gilead, ICON, ViiV

Paul E. Sax, MD
Consulting Fee: AbbVie, Bristol-Myers Squibb, Gilead, GlaxoSmithKline/ViiV, Janssen, Merck
Contracted Research: (Paid to institution): Bristol-Myers Squibb, Gilead, GlaxoSmithKline/ViiV

External Reviewer reports the following relationship(s):
Lisa Hightow-Weidman, MD, MPH 
No relevant financial relationships to disclose.

National Jewish Health and Vindico Medical Education staff report the following relationship(s):
Betti Bandura
No relevant financial relationships to disclose.

Mandy Comeau 
No relevant financial relationships to disclose.

Stephanie Corder, ND, RN, CHCP
No relevant financial relationships to disclose.

Jennifer Frederick, PharmD
No relevant financial relationships to disclose.

Lynda Lyons
No relevant financial relationships to disclose.

Signed disclosures are on file at National Jewish Health and Vindico Medical Education.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and National Jewish Health continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and National Jewish Health. Neither Vindico Medical Education, National Jewish Health, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME
Forefront Collaborative
Rethinking Migraine Treatment: Highlights and Recent Advances

Rethinking Migraine Treatment: Highlights and Recent Advances

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: December 11, 2018
Expires: December 10, 2019
15 minutes to complete

Accredited By

Target Audience

This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
  • Describe major emerging acute and preventive migraine therapies.

Activity Description

Paradigm shift, or shattered? The thinking around both preventive and acute treatment of migraine is amidst a radical change. From a new class of treatment targeting disease-specific pathophysiology to emerging therapies incorporating neuromodulatory devices, Stewart Tepper, MD, gets practicing clinicians up to speed in a Hot Topics Webinar that details the key treatment advances transforming migraine care.

Statement of Educational Need

With the recent approvals of new breakthroughs, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).

Agenda

New Horizons in Headache Treatment
Pathophysiology and Neurotransmitter Targets
New Devices and Medications for Delivering Medications
New Acute Treatment Classes
Prevention: MABs
Neuromodulation for Headache

Faculty

Stewart J. Tepper, MD
Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Allergan, Alphasights, Amgen, Autonomic Technologies, Axsome Therapeutics, Cefaly, Charleston Laboratories, DeepBench, Dr. Reddy’s Laboratories, electroCore, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, Magellan Rx Management,  Neurolief, Nordic BioTech, Pfizer, Scion Neurostim, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Dr. Reddy’s Laboratories, electroCore, eNeura, Scion Neurostim, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva Pharmaceutical Industries.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:

  • Planner (Forefront Collaborative): Katie Detzler

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 3 out of 3. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Content Review Statement

The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions about the Activity

Lily_Zurkovsky@forefrontcollab.com
317.846.2770

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: December 11, 2018
Expires: December 10, 2019
15 minutes to complete

Accredited By

Target Audience

This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
  • Describe major emerging acute and preventive migraine therapies.

Activity Description

Paradigm shift, or shattered? The thinking around both preventive and acute treatment of migraine is amidst a radical change. From a new class of treatment targeting disease-specific pathophysiology to emerging therapies incorporating neuromodulatory devices, Stewart Tepper, MD, gets practicing clinicians up to speed in a Hot Topics Webinar that details the key treatment advances transforming migraine care.

Statement of Educational Need

With the recent approvals of new breakthroughs, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).

Agenda

New Horizons in Headache Treatment
Pathophysiology and Neurotransmitter Targets
New Devices and Medications for Delivering Medications
New Acute Treatment Classes
Prevention: MABs
Neuromodulation for Headache

Faculty

Stewart J. Tepper, MD
Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Allergan, Alphasights, Amgen, Autonomic Technologies, Axsome Therapeutics, Cefaly, Charleston Laboratories, DeepBench, Dr. Reddy’s Laboratories, electroCore, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, Magellan Rx Management,  Neurolief, Nordic BioTech, Pfizer, Scion Neurostim, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Dr. Reddy’s Laboratories, electroCore, eNeura, Scion Neurostim, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva Pharmaceutical Industries.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:

  • Planner (Forefront Collaborative): Katie Detzler

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 3 out of 3. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Content Review Statement

The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions about the Activity

Lily_Zurkovsky@forefrontcollab.com
317.846.2770

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
Vindico
Advances in the Treatment of Peanut Allergy: Rapid Response from Seattle

Advances in the Treatment of Peanut Allergy: Rapid Response from Seattle

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: November 30, 2018
Expires: November 30, 2019
0.75 hours to complete

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Faculty

Activity Chair:
J. Andrew Bird, MD
J. Andrew Bird, MD
Associate Professor of Pediatrics
Division of Allergy and Immunology
University of Texas Southwestern Medical Center
Director, Food Allergy Center
Children’s Medical Center of Dallas
Dallas, TX

Disclosure: Consulting Fee: Aimmune, DBV Technologies, Pharm-Olam
Non-CME Services Fees: Aimmune, DBV Technologies
Contracted Research: Aimmune, DBV Technologies


Faculty:
Ruchi S. Gupta, MD, MPH
Ruchi S. Gupta, MD, MPH
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director
Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL

Disclosure: Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group


Edwin H. Kim, MD, MS
Edwin H. Kim, MD, MS
Director, UNC Food Allergy Initiative
University of North Carolina at Chapel Hill
Chapel Hill, NC

Disclosure: Consulting Fee: Aimmune, DBV Technologies
Contracted Research: Aimmune, Astellas, DBV Technologies, FARE, HAL Allergy
Research Support: Wallace Foundation


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Activity Description

The prevalence of peanut allergy in adults and children continues to increase, significantly disrupting the lives of the millions of affected individuals as well as their families. Although no therapies have been approved for the treatment of peanut allergies, several are currently being evaluated in clinical studies, providing the potential for safe and effective therapeutic options. Within this Rapid Response from Seattle, experts in the field examine the prevalence and burden of IgE-mediated food allergy with a focus on peanut allergy, assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy, and evaluate the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Examine the prevalence and burden of IgE-mediated food allergy, with a focus on peanut allergy.
  • Assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy.
  • Examine the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.

Target Audience

The intended audience for the activity is allergists, immunologists and other health care professionals involved in the treatment of patients with food allergies, particularly peanut allergy.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s) Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Aimmune Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: November 30, 2018
Expires: November 30, 2019
0.75 hours to complete

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Faculty

Activity Chair:
J. Andrew Bird, MD
J. Andrew Bird, MD
Associate Professor of Pediatrics
Division of Allergy and Immunology
University of Texas Southwestern Medical Center
Director, Food Allergy Center
Children’s Medical Center of Dallas
Dallas, TX

Disclosure: Consulting Fee: Aimmune, DBV Technologies, Pharm-Olam
Non-CME Services Fees: Aimmune, DBV Technologies
Contracted Research: Aimmune, DBV Technologies


Faculty:
Ruchi S. Gupta, MD, MPH
Ruchi S. Gupta, MD, MPH
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director
Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL

Disclosure: Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group


Edwin H. Kim, MD, MS
Edwin H. Kim, MD, MS
Director, UNC Food Allergy Initiative
University of North Carolina at Chapel Hill
Chapel Hill, NC

Disclosure: Consulting Fee: Aimmune, DBV Technologies
Contracted Research: Aimmune, Astellas, DBV Technologies, FARE, HAL Allergy
Research Support: Wallace Foundation


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Activity Description

The prevalence of peanut allergy in adults and children continues to increase, significantly disrupting the lives of the millions of affected individuals as well as their families. Although no therapies have been approved for the treatment of peanut allergies, several are currently being evaluated in clinical studies, providing the potential for safe and effective therapeutic options. Within this Rapid Response from Seattle, experts in the field examine the prevalence and burden of IgE-mediated food allergy with a focus on peanut allergy, assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy, and evaluate the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Examine the prevalence and burden of IgE-mediated food allergy, with a focus on peanut allergy.
  • Assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy.
  • Examine the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.

Target Audience

The intended audience for the activity is allergists, immunologists and other health care professionals involved in the treatment of patients with food allergies, particularly peanut allergy.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s) Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Aimmune Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Pages